Zensar Technologies Limited (BSE:504067) entered into a definitive agreement to acquire BridgeView Life Sciences, LLC for $25 million on July 17, 2024. As a part of consideration, Zensar Technologies Limited will pay $14 million in cash and additional earnout will be $11 million by 31st December 2027 contingent on achievement of
performance and employment continuity thresholds. The transaction is subject to regulatory approval and the transaction is expected to close within 2-3 weeks subject to the satisfaction of customary closing conditions.